SCHEMBL25317322

SCHEMBL25317322

Cc1cc2c(cc1Br)C(C)NC2=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.46
CES1 P23141 1/20 0.46
HTR2C P28335 2/20 0.37
MKNK1 Q9BUB5 4/20 0.36
MKNK2 Q9HBH9 3/20 0.36
ALDH1A1 P00352 2/20 0.33
PBRM1 Q86U86 2/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
KMT2A Q03164 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
POLB P06746 1/20 0.32
ALDH2 P05091 1/20 0.32
ALDH3A1 P30838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25319420 0.82 ATAD2 (0.38) BCHECES1MKNK1MKNK2ALDH1A1
SCHEMBL25318579 0.81 KDM1A (0.37) MKNK1MKNK2KMT2ATNKS2POLB
SCHEMBL28387516 0.75 MKNK1 (0.36) MKNK1MKNK2ALDH1A1PBRM1CYP1A2
SCHEMBL29978016 0.75 MKNK1 (0.36) MKNK1MKNK2ALDH1A1PBRM1CYP1A2
SCHEMBL2904093 0.73 CYP1A2 (0.42) CES1MKNK1MKNK2PBRM1CYP1A2
SCHEMBL16098250 0.73 CYP1A2 (0.42) CES1MKNK1MKNK2PBRM1CYP1A2
SCHEMBL20529362 0.73 MKNK2 (0.46) CES1HTR2CMKNK1MKNK2PBRM1
SCHEMBL29676714 0.73 CYP1A2 (0.42) CES1MKNK1MKNK2PBRM1CYP1A2
SCHEMBL25320352 0.72 MKNK1 (0.35) MKNK1MKNK2ALDH1A1KDM4E
SCHEMBL23745465 0.72 MKNK2 (0.38) CES1HTR2CMKNK1MKNK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA BCHE 2557/4885CES1 2225/4885HTR2C 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.